Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

July 5, 2019

Study Completion Date

July 5, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

14C-PF-06651600

Oral solution of 200 mg 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

DRUG

14C-PF-06651600 IV

IV solution 60 micrograms of 14C labeled PF-06651600 containing approximately 300 nCi radioactivity

DRUG

PF-06651600

Oral solution 200mg

Trial Locations (2)

9728 NZ

PRA Health Sciences, Groningen

3584 BL

PRA Health Sciences Utrecht, Utrecht

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY